Open Access

Andreas Ziebart, Julia Onken, Minou Nadji-Ohl, Christine Jungk, Stefan Rückriegel, Dorothee Mielke, Rüdiger Gerlach, Marie-Therese Forster, Constantin Roder, Katja Kniese, Nicolas Neidert, Ludovica Fabbrocini, Darius Kalasauskas, Gerges Aziz, Sabrina Riehl, Lennart Sannwald, Benjamin Mayer, Christian Rainer Wirtz, Daniel Sachs, Sebastian Ille, Mario Löhr, Rainer Ritz, Florian Ringel, Florian Ebner, Roland Roelz, Jürgen Beck, Arya Nabavi, Marcos Tatagiba, Marcus Czabanka, Veit Rohde, Ralf-Ingo Ernestus, Sandro Krieg, Oliver Ganslandt, Peter Vajkoczy, Jan Coburger

• Purpose: Recent evidence-based guidelines recommend adjuvant therapy following surgery for most patients with WHO grade 2 and 3 gliomas. However, deviations from these recommendations are frequently observed in clinical practice. This study aimed to evaluate patterns of postoperative management across Germany, using multicentre registry data from certified neuro-oncology centres. Methods: We analysed data from the ongoing multicentre registry study, which prospectively collects adult patients with IDH-mutant WHO grade 2 and 3 diffuse gliomas. Patients treated at 14 certified neuro-oncology centres were included. Multivariate logistic regression was used to identify factors associated with observation, chemotherapy, or radiotherapy. We assessed concordance between guideline recommendations and actual treatment during the first year after surgery. Results: A total of 217 patients with astrocytoma or oligodendroglioma were included, of whom 169 (78%) had WHO grade 2 tumours. ObservationPurpose: Recent evidence-based guidelines recommend adjuvant therapy following surgery for most patients with WHO grade 2 and 3 gliomas. However, deviations from these recommendations are frequently observed in clinical practice. This study aimed to evaluate patterns of postoperative management across Germany, using multicentre registry data from certified neuro-oncology centres. Methods: We analysed data from the ongoing multicentre registry study, which prospectively collects adult patients with IDH-mutant WHO grade 2 and 3 diffuse gliomas. Patients treated at 14 certified neuro-oncology centres were included. Multivariate logistic regression was used to identify factors associated with observation, chemotherapy, or radiotherapy. We assessed concordance between guideline recommendations and actual treatment during the first year after surgery. Results: A total of 217 patients with astrocytoma or oligodendroglioma were included, of whom 169 (78%) had WHO grade 2 tumours. Observation alone was selected in 90 (53%) patients with grade 2 tumours. Gross total resection was independently associated with observation (OR 0.10; 95% CI, 0.04–0.22; p < 0.001). In patients aged ≥ 40 years, adjuvant treatment decisions deviated from current guidelines (OR 3.15; 95% CI, 1.70–5.95; p = 0.001), although age itself was not an independent predictor of treatment choice in multivariate models. Conclusion: The presence of residual tumour after surgery was the principal determinant of postoperative management in patients with WHO grade 2 gliomas. Age ≥ 40 years did not independently influence clinical decision-making. These findings highlight a gap between guidelines and real-world practice and underscore the need for more flexible, individualised treatment frameworks.…